Advocates celebrate 2023 legislation capping insulin prices for people on the state employee health insurance plan in a signing ceremony at the North Dakota Capitol with Gov. Doug Burgum in May 2024. Angela Kritzberger, second from right, and her daughter Nina, third from right, plan to travel to Bismarck this week to testify in favor of a bill to extend the caps to the general North Dakota commercial insurance market. (Mary Steurer/North Dakota Monitor)
Lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for more North Dakotans.
If adopted as currently written, House Bill 1114 would set out-of-pocket costs for a monthly supply of insulin at $25 for the North Dakota commercial insurance market. The same monthly price cap would also apply to medical supplies used to administer insulin.
The new caps would affect North Dakotans on individual and small group insurance plans. The bill doesn’t apply to insurance provided by large employers.
The caps were already piloted for state employee health plans beginning in 2023, which would continue under the proposal.
Advocates attempted to bring a similar bill during the 2023 session. Under state law, however, North Dakota must first pilot any health insurance mandates on state employee health insurance before rolling it out to the full North Dakota marketplace.
“Basically, it acts kind of like a study to see how it impacts the PERS (Public Employees Retirement System) active health insurance plan that includes both state employees and employees of participating political subdivisions,” Rebecca Fricke, executive director of PERS, said.
In the end, the bill — Senate Bill 2140 — was changed to implement a two-year test run of the caps for those on the state plan.
The 2023 legislation specifically instructed PERS to bring a follow-up bill during the 2025 session extending the price caps to the general state insurance marketplace.
Angela Kritzberger, whose daughter Nina has Type 1 diabetes, was one of the advocates who spoke in favor of insulin caps during the 2023 session.
“Our hope was to get it for everyone,” Kritzberger said.
She said she plans to travel to Bismarck this week so her daughter can offer testimony in support of the 2025 bill.
The bill received recommendation from the interim Employee Benefits Programs Committee and was introduced by the House Government and Veterans Affairs Committee.
“This is a very positive move for persons who need this kind of care, and it’s a very positive thing for our society,” said Sen. Tim Mathern, D-Fargo, the lead sponsor of the 2023 version of the bill.
House Bill 1114 is scheduled for a hearing before the Government and Veterans Affairs Committee on Thursday at 10:15 a.m.
Written testimony on the bill may be submitted to the committee by 7:45 a.m. Thursday.
Last session, the Greater North Dakota Chamber of Commerce spoke against insulin caps, cautioning against government intervention in the free market. The chamber also said that many insulin manufacturers and health insurers have already voluntarily lowered prices for insulin for consumers.
The three largest manufacturers for the U.S. insulin market — Eli Lilly, Novo Nordisk and Sanofi — all recently lowered the cost of their insulin products.
Owing in part to those price cuts, the PERS board found that the pilot program didn’t come at a significant cost to the state.
As North Dakota legislative session is set to begin, lawmakers have limited time to introduce bills
In a study presented by PERS to the interim Employee Benefits Programs Committee, Deloitte consultants found that continuing the caps for the 2025-2027 biennium would result in an estimated 0.12% increase in claims costs to the state insurance program, or roughly $1 million.
The fiscal note attached to bill House Bill 1114 estimates the cost to the state at about $834,000.
The Deloitte study also reported that as of August, 24 states and Washington, D.C., had also implemented insulin price limits for state-regulated commercial health insurance plans.
New insulin caps went into effect Jan. 1 for Affordable Care Act-compliant individual and small group plans in North Dakota. Jacob Just, director of communications for the North Dakota Insurance Department, said these caps essentially cover the same plans as House Bill 1114.
“This bill would just look to codify what has already been in effect,” Just said. The Insurance Department will be offering neutral testimony on the bill, he added.
Kritzberger said that even if the market is lowering insulin prices, putting the caps into state law are needed to ensure prices don’t swell again.
When insulin is prohibitively expensive, diabetes patients may forego treatment — which can cause life-threatening health complications, she said.
“I think we’ve seen what the market can do,” Kritzberger said.
YOU MAKE OUR WORK POSSIBLE.
GET THE MORNING HEADLINES.
by Mary Steurer, North Dakota Monitor
January 7, 2025
by Mary Steurer, North Dakota Monitor
January 7, 2025
Lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for more North Dakotans.
If adopted as currently written, House Bill 1114 would set out-of-pocket costs for a monthly supply of insulin at $25 for the North Dakota commercial insurance market. The same monthly price cap would also apply to medical supplies used to administer insulin.
The new caps would affect North Dakotans on individual and small group insurance plans. The bill doesn’t apply to insurance provided by large employers.
The caps were already piloted for state employee health plans beginning in 2023, which would continue under the proposal.
Advocates attempted to bring a similar bill during the 2023 session. Under state law, however, North Dakota must first pilot any health insurance mandates on state employee health insurance before rolling it out to the full North Dakota marketplace.
“Basically, it acts kind of like a study to see how it impacts the PERS (Public Employees Retirement System) active health insurance plan that includes both state employees and employees of participating political subdivisions,” Rebecca Fricke, executive director of PERS, said.
In the end, the bill — Senate Bill 2140 — was changed to implement a two-year test run of the caps for those on the state plan.
The 2023 legislation specifically instructed PERS to bring a follow-up bill during the 2025 session extending the price caps to the general state insurance marketplace.
Angela Kritzberger, whose daughter Nina has Type 1 diabetes, was one of the advocates who spoke in favor of insulin caps during the 2023 session.
“Our hope was to get it for everyone,” Kritzberger said.
She said she plans to travel to Bismarck this week so her daughter can offer testimony in support of the 2025 bill.
The bill received recommendation from the interim Employee Benefits Programs Committee and was introduced by the House Government and Veterans Affairs Committee.
“This is a very positive move for persons who need this kind of care, and it’s a very positive thing for our society,” said Sen. Tim Mathern, D-Fargo, the lead sponsor of the 2023 version of the bill.
House Bill 1114 is scheduled for a hearing before the Government and Veterans Affairs Committee on Thursday at 10:15 a.m.
Written testimony on the bill may be submitted to the committee by 7:45 a.m. Thursday.
Last session, the Greater North Dakota Chamber of Commerce spoke against insulin caps, cautioning against government intervention in the free market. The chamber also said that many insulin manufacturers and health insurers have already voluntarily lowered prices for insulin for consumers.
The three largest manufacturers for the U.S. insulin market — Eli Lilly, Novo Nordisk and Sanofi — all recently lowered the cost of their insulin products.
Owing in part to those price cuts, the PERS board found that the pilot program didn’t come at a significant cost to the state.
As North Dakota legislative session is set to begin, lawmakers have limited time to introduce bills
In a study presented by PERS to the interim Employee Benefits Programs Committee, Deloitte consultants found that continuing the caps for the 2025-2027 biennium would result in an estimated 0.12% increase in claims costs to the state insurance program, or roughly $1 million.
The fiscal note attached to bill House Bill 1114 estimates the cost to the state at about $834,000.
The Deloitte study also reported that as of August, 24 states and Washington, D.C., had also implemented insulin price limits for state-regulated commercial health insurance plans.
New insulin caps went into effect Jan. 1 for Affordable Care Act-compliant individual and small group plans in North Dakota. Jacob Just, director of communications for the North Dakota Insurance Department, said these caps essentially cover the same plans as House Bill 1114.
“This bill would just look to codify what has already been in effect,” Just said. The Insurance Department will be offering neutral testimony on the bill, he added.
Kritzberger said that even if the market is lowering insulin prices, putting the caps into state law are needed to ensure prices don’t swell again.
When insulin is prohibitively expensive, diabetes patients may forego treatment — which can cause life-threatening health complications, she said.
“I think we’ve seen what the market can do,” Kritzberger said.
YOU MAKE OUR WORK POSSIBLE.
GET THE MORNING HEADLINES.
North Dakota Monitor is part of States Newsroom, a nonprofit news network supported by grants and a coalition of donors as a 501c(3) public charity. North Dakota Monitor maintains editorial independence. Contact Editor Amy Dalrymple for questions: info@northdakotamonitor.com.
Our stories may be republished online or in print under Creative Commons license CC BY-NC-ND 4.0. We ask that you edit only for style or to shorten, provide proper attribution and link to our website. AP and Getty images may not be republished. Please see our republishing guidelines for use of any other photos and graphics.
Mary Steurer is a reporter based in Bismarck. A native of St. Louis, Steurer most recently worked as the local government reporter for the Casper Star-Tribune newspaper in Wyoming.
North Dakota Monitor is part of States Newsroom, the nation’s largest state-focused nonprofit news organization.
DEMOCRACY TOOLKIT
© North Dakota Monitor, 2025
v1.67.1
North Dakota Monitor is a nonprofit, nonpartisan source for trusted news, commentary and insight into statewide policy and critical issues affecting the Peace Garden State.
We’re part of States Newsroom, the nation’s largest state-focused nonprofit news organization.
DEIJ Policy | Ethics Policy | Privacy Policy
Our stories may be republished online or in print under Creative Commons license CC BY-NC-ND 4.0. We ask that you edit only for style or to shorten, provide proper attribution and link to our website. (See full republishing guidelines.)
© North Dakota Monitor, 2025